Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared a post on X:
“Highlighting key data points on clinical trials utilizing upfront venetoclax for intensive eligible treatment naive AML.
By no means a cross-trial comparison.”
Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared a post on X:
“Highlighting key data points on clinical trials utilizing upfront venetoclax for intensive eligible treatment naive AML.
By no means a cross-trial comparison.”